Thank you. That's an excellent question. There are actually a couple of topics there.
First of all, TRIUMF has licensed its cyclotron technology to a company in Richmond, British Columbia, known as Advanced Cyclotron Systems Inc. I'm not an expert on their business negotiations, but I believe they're in the process of selling a TRIUMF-designed cyclotron to Thunder Bay. We've had representatives of TRIUMF in Thunder Bay to discuss cyclotron technologies and how to grow that. Actually, I believe that's an excellent example of how the distributed model of producing isotopes can make a difference.
We're in similar discussions in Prince George with UNBC about how to deploy a cyclotron there.
With regard to your question concerning the $222 million, we certainly do know how it's allocated. It covers a variety of research and development programs focusing on particle physics, some nuclear science, this new accelerator technology, and a mainstream nuclear medicine program.
TRIUMF is a publicly funded enterprise, so we're not in a position to contract and sell equipment to Thunder Bay; however, we are the technical backstop for the existing Canadian providers of that. So we look forward to having Thunder Bay join the nuclear medicine network as one of the leaders of both practice and research.